X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://pharmaphorum.com/news/cstone-gets-a-win-for-sugemalimab-in-oesophageal-cancer/
https://www.pharmatimes.com/news/eqrx_receives_mhra_marketing_approval_for_sugemalimab_1484724
https://www.statnews.com/2022/11/10/for-its-first-two-medicines-eqrx-abandons-its-bold-strategy-to-lower-drug-prices/
https://www.pharmatimes.com/news/eqrx_announces_further_results_from_phase_3_trial_of_sugemalimab_1453117
https://www.prnewswire.com/news-releases/cstone-presents-updated-results-of-a-registrational-study-of-sugemalimab-in-patients-with-stage-iii-nsclc-via-oral-presentation-at-wclc-2022-301601233.html
https://www.fiercepharma.com/pharma/pfizer-partner-cstone-explores-sale-us-path-blocked-chinese-competition-heats-bloomberg
https://www.asiaone.com/business/cstone-and-pfizer-announce-nmpa-approval-sugemalimab-patients-unresectable-stage-iii-non
https://www.asiaone.com/business/cstone-announced-two-key-phase-3-registrational-clinical-trials-sugemalimab-completed
https://www.prnewswire.com/news-releases/cstone-announces-the-gemstone-302-study-of-sugemalimab-met-the-endpoint-of-overall-survival-in-the-first-line-treatment-of-metastatic-non-small-cell-lung-cancer-patients-301462818.html
https://www.asiaone.com/business/cstone-announces-clinical-data-registrational-study-sugemalimab-stage-iii-non-small-cell
https://www.prnewswire.com/news-releases/cstone-announced-new-drug-approval-of-cejemly-sugemalimab-in-china-to-potentially-reshape-the-landscape-of-immuno-oncology-therapy-in-lung-cancer-301448778.html
https://www.biospace.com/article/releases/cstone-announced-new-drug-approval-of-cejemly-sugemalimab-in-china-to-potentially-reshape-the-landscape-of-immuno-oncology-therapy-in-lung-cancer/
https://www.prnewswire.com/news-releases/cstone-and-eqrx-enter-global-strategic-partnership-for-two-immune-checkpoint-inhibitors-sugemalimab-anti-pd-l1-and-cs1003-anti-pd-1-301159962.html
https://pharmaphorum.com/news/pfizer-picks-up-rights-to-cstones-cancer-immunotherapy-sugemalimab-in-china/
https://www.businesswire.com/news/home/20200929006175/en/CStone-Pfizer-Enter-into-Strategic-Collaboration-to-Address-Oncological-Needs-in-China
https://www.prnewswire.com/news-releases/first-patient-dosed-in-phase-iii-gemstone-303-study-for-cs1001-in-combination-with-chemotherapy-in-first-line-gastric-adenocarcinoma-and-gastro-esophageal-junction-adenocarcinoma-300832689.html
http://www.prnewswire.com/news-releases/innovative-biotech-company-cstone-pharmaceuticals-receives-150-million-dollars-in-series-a-financing-to-focus-on-addressing-the-specific-needs-of-chinese-patients-300293578.html
Market Place
Share 
